BACKGROUND: Psoriasin (S100A7) expression has previously been associated with psoriasiform hyperplasia as well as with tumor progression in breast cancer. Its expression profile for different stages of skin lesions is unknown. The aim of this study was to determine the relationship between psoriasin (S100A7) and tumor progression in skin. METHODS: Psoriasin was assessed by immunohistochemistry and levels of expression determined by semi-quantitative scoring in skin biopsies from 50 patients. The cohort included normal skin, actinic keratosis, squamous carcinoma in-situ, invasive squamous cell carcinoma, and basal cell carcinoma. RESULTS: In normal skin, psoriasin was rarely detected in epidermis but was expressed in underlying adnexae. In abnormal epidermis psoriasin was frequently expressed in abnormal keratinocytes in actinic keratosis, in-situ and invasive squamous cell carcinoma, but was rarely observed in the basal epidermal layer or in superficial or invasive basal cell carcinoma. The highest levels of expression were seen within squamous carcinoma in-situ. Significantly reduced levels of expression were observed in both unmatched (p = 0.0001) and matched (p < 0.004) invasive squamous cell carcinoma. Psoriasin expression within abnormal squamous lesions correlated with mitotic count (r = 0.54, p = 0.0036), however no significant relation was found with the intensity of dermal inflammatory cell infiltrates assessed within each pathology. CONCLUSION: These results suggest that altered psoriasin expression occurs in abnormal epidermis and that downregulation may be related to the onset of invasion in squamous cell carcinoma in skin.
BACKGROUND: Psoriasin (S100A7) expression has previously been associated with psoriasiform hyperplasia as well as with tumor progression in breast cancer. Its expression profile for different stages of skin lesions is unknown. The aim of this study was to determine the relationship between psoriasin (S100A7) and tumor progression in skin. METHODS: Psoriasin was assessed by immunohistochemistry and levels of expression determined by semi-quantitative scoring in skin biopsies from 50 patients. The cohort included normal skin, actinic keratosis, squamous carcinoma in-situ, invasive squamous cell carcinoma, and basal cell carcinoma. RESULTS: In normal skin, psoriasin was rarely detected in epidermis but was expressed in underlying adnexae. In abnormal epidermis psoriasin was frequently expressed in abnormal keratinocytes in actinic keratosis, in-situ and invasive squamous cell carcinoma, but was rarely observed in the basal epidermal layer or in superficial or invasive basal cell carcinoma. The highest levels of expression were seen within squamous carcinoma in-situ. Significantly reduced levels of expression were observed in both unmatched (p = 0.0001) and matched (p < 0.004) invasive squamous cell carcinoma. Psoriasin expression within abnormal squamous lesions correlated with mitotic count (r = 0.54, p = 0.0036), however no significant relation was found with the intensity of dermal inflammatory cell infiltrates assessed within each pathology. CONCLUSION: These results suggest that altered psoriasin expression occurs in abnormal epidermis and that downregulation may be related to the onset of invasion in squamous cell carcinoma in skin.
Authors: Charlotta Enerbäck; Dale A Porter; Pankaj Seth; Dennis Sgroi; Justine Gaudet; Stanislawa Weremowicz; Cynthia C Morton; Stuart Schnitt; Robert L Pitts; Jason Stampl; Kerry Barnhart; Kornelia Polyak Journal: Cancer Res Date: 2002-01-01 Impact factor: 12.701
Authors: S Di Nuzzo; R M Sylva-Steenland; C W Koomen; M A de Rie; P K Das; J D Bos; M B Teunissen Journal: Photochem Photobiol Date: 2000-09 Impact factor: 3.421
Authors: Y Bronckart; C Decaestecker; N Nagy; L Harper; B W Schäfer; I Salmon; R Pochet; R Kiss; C W Heizman Journal: Histol Histopathol Date: 2001-07 Impact factor: 2.303
Authors: Fred van Ruissen; Bastiaan J H Jansen; Gys J de Jongh; Ivonne M J J van Vlijmen-Willems; Joost Schalkwijk Journal: FASEB J Date: 2001-12-28 Impact factor: 5.191
Authors: P Madsen; H H Rasmussen; H Leffers; B Honoré; K Dejgaard; E Olsen; J Kiil; E Walbum; A H Andersen; B Basse Journal: J Invest Dermatol Date: 1991-10 Impact factor: 8.551
Authors: Noemi Moubayed; Michael Weichenthal; Jürgen Harder; Elke Wandel; Michael Sticherling; Regine Gläser Journal: J Cancer Res Clin Oncol Date: 2006-11-29 Impact factor: 4.553
Authors: Nathan R West; Benjamin Farnell; Jill I Murray; Fraser Hof; Peter H Watson; Martin J Boulanger Journal: Protein Sci Date: 2009-12 Impact factor: 6.725
Authors: James A DeVoti; David W Rosenthal; Rong Wu; Allan L Abramson; Bettie M Steinberg; Vincent R Bonagura Journal: Mol Med Date: 2008 Sep-Oct Impact factor: 6.354
Authors: Eva Hattinger; Stephanie Zwicker; Thomas Ruzicka; Stuart H Yuspa; Ronald Wolf Journal: Curr Opin Pharmacol Date: 2013-05-09 Impact factor: 5.547
Authors: Vikram Paruchuri; Anil Prasad; Kevin McHugh; Hari K Bhat; Kornelia Polyak; Ramesh K Ganju Journal: PLoS One Date: 2008-03-05 Impact factor: 3.240